|
US2009253184A1
|
|
Compositions and methods related to an adenoviral trans-complementing cell line
|
|
US2010209451A1
|
|
Compositions and Methods Related to Adenovirus Based Delivery of Antigens
|
|
US2008044378A1
|
|
Methods and Compositions for Protein Production Using Adenoviral Vectors
|
|
US2007281041A1
|
|
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
|
US2007231304A1
|
|
Prognostic factors for anti-hyperproliferative disease gene therapy
|
|
US2007172846A1
|
|
Methods for the Production and Purification of Adenoviral Vectors
|
|
EP1888105A2
|
|
P53 vaccines for the treatment of cancers
|
|
CN101166546A
|
|
Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
|
|
AU2006206267A1
|
|
Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
|
|
WO2006069389A1
|
|
Use of flexible bag containers for viral production
|
|
CA2588157A1
|
|
Cancer immunotherapy incorporating p53
|
|
CA2586107A1
|
|
A novel method for the production and purification of adenoviral vectors
|
|
US2006052322A1
|
|
Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
|
|
WO2005107474A2
|
|
Oncolytic adenovirus armed with therapeutic genes
|
|
US2008293652A1
|
|
Combination of Ad-P53 and Chemotherapy for the Treatment of Tumours
|
|
WO2005082396A2
|
|
Use of mda-7 to inhibit infection by pathogenic organisms
|
|
AU2003300401A1
|
|
p53 treatment of papillomavirus and carcinogen-transformed cells in hyperplastic lesions
|
|
CA2496918A1
|
|
Chromatographic methods for adenovirus purification
|
|
US2003224354A1
|
|
Quantifying viral particles with intrinsic fluorescence
|
|
US2004229335A1
|
|
Methods and compositions for the production of adenoviral vectors
|
